Replies to post #103852 on Biotech Values

[DewDiligence]

ABT reports 9-month interim data for bioresorbable stent:

http://finance.yahoo.com/news/Abbotts-Fully-Bioresorbable-prnews-2799247793.html?x=0&.v=1

At nine months, Abbott's bioresorbable vascular scaffold (BVS) demonstrated strong results that remained consistent with the six-month data from the same 45-patient group, with the rate of major adverse cardiac events (MACE) unchanged at 4.4 percent and no reports of blood clots (thromboses). These results were presented during the Cardiovascular Research Foundation's 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) conference in Washington, D.C.

Six-month data from the patient cohort (n=101) who received the redesigned stent were reported in Jun 2010 (#msg-50956393).